Evaluating only Synta Pharmaceuticals’s profile at its peak — without knowing the outcome — the model ranked Founder chaos as the #1 likely cause. Documented cause: No market fit.
Key Events Timeline
FOUNDING
Synta Pharmaceuticals founded
FUNDING
Synta advances ganetespib into clinical development with significant capital raises
PRODUCT LAUNCH
GALAXY-2 Phase 3 trial for ganetespib in non-small cell lung cancer initiates enrollment
Slow Death: Synta Pharmaceuticals ceases operations via reverse merger with Madrigal Pharmaceuticals after burning $400M+ with no pipeline backup
Full Analysis
Free · no account needed
Documented cause
Synta spent 16 years developing ganetespib, an HSP90 inhibitor for non-small cell lung cancer. The Phase 3 GALAXY-2 trial failed primary endpoint in 2016. With no backup assets and $400M+ burned, Synta reverse-merged with Madrigal Pharmaceuticals, effectively dissolving the original entity.
Lesson
“Biotech companies with one Phase 3 asset and no backup pipeline are structurally unable to survive a clinical failure. Pipeline diversification is not a luxury in oncology; it is minimum viable company structure.”